Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

2 recalls, newest first

Class II · Moderate risk

Dabigatran Etexilate Capsules

CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.

Ongoing Nitrosamine impurity Ascend Laboratories, LLC NDC 67877-474-60 D-0533-2023

Recalls by year